The use of dupilumab for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents. The association between dupilumab and psoriasis ...

SAN DIEGO, CA, USA I July 09, 2025 I Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on ...

Nela Richardson, ADP chief economist and a Bloomberg contributor, reacts to the latest jobless claims numbers, saying the US labor market is very concentrated and only hiring a very specific type ...

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on ...

Investing.com -- Apogee (NASDAQ: APOG) Therapeutics, Inc. (NASDAQ: APGE) stock surged 24% on Monday after the clinical-stage biotechnology company announced positive 16-week data from its Phase 2 ...

The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007 in patients with moderate-to-severe atopic dermatitis Topline data expected in the fourth quarter of 2026 SAN DIEGO, July 01, ...

Take a look at the Console Launch Trailer for Stasis, a point-and-click adventure game developed by The Brotherhood. Players will explore a distant future as John Maracheck aboard a spacecraft ...

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on high-certainty data, offering new options for those with mild to severe ...

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate to severe atopic dermatitis, meeting its primary and secondary ...

The Phase 1b trial is designed to evaluate the safety, tolerability, pharmacokinetics, target engagement, and early signs of efficacy of ENV-294 in patients with moderate to severe atopic dermatitis.